As families who have a predominance of premenopausal breast cancer are more likely to have mutations in BRCA1 or BRCA2 than in TP53[11], we started our diagnostic work-up with Sanger sequencing and MLPA (Multiplex Ligation-dependent Probe Amplification) of the two breast cancer genes. This evidence concerns the gene BRCA2 and breast cancer.